This is a novel, fixed-dose combination of Estradiol, a natural estrogen, and Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor. It is designed to address both the underlying hormonal deficiency and the resultant vascular/sexual dysfunction in postmenopausal women. Estradiol provides systemic relief from menopausal symptoms and improves vaginal epithelial health, while Sildenafil enhances clitoral and vaginal blood flow, potentially improving sexual arousal, sensation, and reducing dyspareunia. This combination is a targeted therapy for female sexual dysfunction (FSD) in the context of menopause, particularly for hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD).
Adult: Dosage must be individualized. A typical investigational regimen might be Estradiol 1.0 mg + Sildenafil 50 mg, taken orally once daily. For arousal-specific issues, Sildenafil component may be taken on an 'as-needed' basis approximately 1 hour before sexual activity, while Estradiol is taken daily. Starting dose of Sildenafil is often 25-50 mg.
Note: Take with or without food. However, a high-fat meal can delay Sildenafil absorption. Swallow tablet whole with a glass of water. For 'as-needed' Sildenafil dosing, take approximately 30-60 minutes before anticipated sexual activity. Do not take more than one dose in a 24-hour period.
The combination works via two synergistic pathways. Estradiol acts as the primary estrogenic hormone, reversing urogenital atrophy, increasing vaginal lubrication and blood flow, and improving central nervous system modulation of sexual desire. Sildenafil, by inhibiting PDE5 in the clitoral and vaginal smooth muscle and vasculature, increases intracellular cyclic guanosine monophosphate (cGMP), leading to nitric oxide (NO)-mediated vasodilation and enhanced genital blood flow, engorgement, and sensation.
Pregnancy: CONTRANDICATED. Estradiol is Pregnancy Category X. Sildenafil is Category B, but the combination is absolutely not for use during pregnancy. May cause fetal harm.
Driving: May cause dizziness, visual disturbances, and syncope, especially in combination with alcohol. Patients should be cautioned about driving or operating machinery until they know how the medication affects them.
| Nitrates (Nitroglycerin, Isosorbide) | Profound, life-threatening hypotension. | Contraindicated |
| Potent CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Ritonavir, Clarithromycin) | Markedly increases Sildenafil plasma levels, increasing toxicity risk. Dose reduction of Sildenafil component is mandatory. | Major |
| Alpha-blockers (Doxazosin, Tamsulosin) | Additive vasodilation and hypotension. | Major |
| Antihypertensives | Potential additive blood pressure lowering effect. | Moderate |
| CYP3A4 Inducers (Rifampicin, Carbamazepine, Phenytoin, St. John's Wort) | Decreases Sildenafil and Estradiol plasma levels, reducing efficacy. | Moderate |
| Warfarin | Estradiol may increase or decrease anticoagulant effect; monitor INR closely. | Moderate |
| Hepatotoxic drugs (e.g., high-dose Paracetamol, Methotrexate) | Increased risk of liver damage. | Moderate |
| Corticosteroids | Enhanced estrogenic effect. | Moderate |
| Grapefruit Juice | Inhibits CYP3A4, increasing Sildenafil levels and side effects. | Moderate |
Same composition (Estradiol (NA) + Sildenafil (NA)), different brands: